Exploring Novel Therapeutics for Acute Ischemic Stroke

Abstract

Stroke remains one of the leading causes of morbidity and mortality worldwide, with ischemic stroke accounting for nearly 80–85% of all cases. It occurs due to obstruction of cerebral blood flow by thrombus or embolus, leading to irreversible neuronal death in the ischemic core and salvageable but vulnerable tissue in the penumbra. Despite the established role of intravenous recombinant tissue plasminogen activator (rtPA) as the only FDA-approved pharmacological therapy, its limited therapeutic window and modest efficacy highlight the urgent need for more effective interventions. Advances in neuroprotective strategies, stem cell therapy, and gene therapy have shown potential by targeting excitotoxicity, oxidative stress, apoptosis, and neuroinflammation, though translation from preclinical studies to clinical success remains challenging. Mechanical thrombectomy has transformed acute ischemic stroke management, offered rapid reperfusion and improved functional outcomes, particularly in large vessel occlusions. Next-generation thrombectomy devices—including refined stent retrievers (e.g., Embotrap, Tigertriever, NeVa), aspiration systems (e.g., Penumbra ACE, React Catheter), and hybrid approaches (e.g., Solumbra technique, balloon guide catheters such as FlowGate^2 and Walrus)—have achieved recanalization rates exceeding 90% in clinical trials. Emerging technologies, including laser-based clot fragmentation, ultrasound-assisted thrombectomy, micro-net mesh systems, and robotics-assisted interventions, are under active investigation to expand treatment options, improve safety, and extend access, especially in remote settings. The growing emphasis on multimodal approaches integrating pharmacological, regenerative, and mechanical strategies reflects a paradigm shift in stroke care. Future directions will focus on optimizing device design, enhancing neuroprotective adjuncts, and personalizing therapies to reduce disability and global stroke burden.

Introduction

Stroke, particularly acute ischemic stroke (AIS), is a serious and life-threatening condition caused by interrupted blood flow to the brain, leading to rapid brain cell death and long-term neurological damage. Stroke is one of the leading causes of death and disability worldwide and places a major burden on healthcare systems and economies.

Strokes are classified into three main types: ischemic stroke, hemorrhagic stroke, and transient ischemic attack (TIA). Ischemic stroke is the most common form, accounting for about 80–85% of cases, and usually results from thrombus or embolus formation that blocks cerebral arteries. Major ischemic stroke types include thrombotic, embolic, and lacunar strokes.

Risk factors include hypertension, diabetes, abnormal cholesterol levels, smoking, physical inactivity, air pollution, and cardiovascular diseases such as atrial fibrillation. These modifiable factors contribute to more than 80% of the global stroke burden. Rare causes include genetic disorders, infections, blood diseases, and vascular abnormalities.

Current treatment strategies focus on restoring blood flow quickly through thrombolytic therapy such as recombinant tissue plasminogen activator (rtPA), antiplatelet therapy, and mechanical thrombectomy. Although rtPA is FDA-approved and improves outcomes in some patients, treatment success remains limited, and many neuroprotective drugs that worked in animal studies have shown poor results in humans.

The pathophysiology of ischemic stroke involves formation of an ischemic core, where severe blood flow reduction causes irreversible neuronal death, and an ischemic penumbra, a surrounding area with partially preserved blood flow that can potentially recover if treated rapidly. Secondary injury mechanisms such as oxidative stress, inflammation, apoptosis, mitochondrial dysfunction, and blood–brain barrier disruption further worsen brain damage.

Globally, ischemic stroke affects nearly 70 million people, causing around 7.8 million new cases and 3.6 million deaths annually. While age-standardized stroke rates have declined due to improved prevention and care, the overall burden continues to rise because of aging populations and increasing risk factors, especially in low- and middle-income countries. Regions such as Eastern Europe, Sub-Saharan Africa, and parts of Asia experience particularly high stroke burdens.

Conclusion

Acute ischemic stroke continues to be a major cause of death and disability around the globe, highlighting the pressing need for new strategies that focus on both immediate care and long-term recovery. While intravenous thrombolysis with rtPA and mechanical thrombectomy are currently the primary treatments for restoring blood flow, their limited treatment windows and associated risks often leave many patients without effective options. This situation emphasizes the importance of creating additional strategies that not only restore blood circulation but also protect and mend brain tissue. New neuroprotective drugs have shown promising potential in reducing excitotoxicity, oxidative damage, and inflammation, which are critical processes that lead to neuronal injury in the ischemic penumbra. At the same time, advancements in stem cell and gene therapy are paving the way for new and exciting opportunities to encourage neurogenesis, angiogenesis, and functional brain repair, although challenges related to safety, delivery methods, and clinical application still need to be tackled. The emergence of next-generation mechanical thrombectomy technologies, including laser- and ultrasound-assisted systems, has also enhanced revascularization outcomes and expanded the treatment window. As we look to the future, the most exciting possibility involves integrating pharmacological, cellular, and mechanical treatments into a personalized, multimodal approach, supported by biomarkers and cutting-edge neuroimaging to guide therapy. Making this vision a reality will require close teamwork between scientists and clinicians to transform laboratory innovations into practical treatments that can reduce disability, enhance recovery, and ultimately lessen the global impact of ischemic stroke.

References

[1] Tomkins AJ, Hood RJ, Levi CR, Spratt NJ. Tissue Plasminogen Activator for preclinical stroke research: Neither “rat” nor “human” dose mimics clinical recanalization in a carotid occlusion model. Scientific Reports. 2015 Nov 2;5(1):16026. [2] Davenport R, Dennis M. Neurological emergencies: acute stroke. Journal of Neurology, Neurosurgery & Psychiatry. 2000 Mar 1;68(3):277-88. [3] Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. stroke. 2007 Mar 1;38(3):967-73. [4] Kalladka D, Muir KW. Brain repair: cell therapy in stroke. Stem Cells and Cloning: Advances and Applications. 2014 Feb 21:31-44. [5] He G, Yi T, Deng J, Wei L, Lu H, Lin D, Lin X, Zhang Y, Miao G, Liang D, Chen W. Successful reperfusion for better outcomes in medium vessel occlusion: Penumbral salvage versus infarct volume reduction. European Stroke Journal. 2025 Jul 29:23969873251360492. [6] ATLANTIS T. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. The Lancet. 2004 Mar 6;363(9411):768-74. [7] Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. The Lancet. 2008 May 10;371(9624):1612-23. [8] Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. stroke. 2018 Mar;49(3): e46-99. [9] O\'Collins VE, Macleod MR, Donnan GA, Horky LL, Van Der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Annals of neurology. 2006 Mar;59(3):467-77. [10] Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends in neurosciences. 1999 Sep 1;22(9):391-7. [11] Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh 3rd EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. stroke. 1993 Jan;24(1):35-41. [12] Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh 3rd EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. stroke. 1993 Jan;24(1):35-41. [13] Benitez S, Puig N, Camps-Renom P, Sánchez-Quesada JL. Atherogenic circulating lipoproteins in ischemic stroke. Frontiers in Cardiovascular Medicine. 2024 Dec 6; 11:1470364. [14] Gallo G, Volpe M, Savoia C. Endothelial dysfunction in hypertension: current concepts and clinical implications. Frontiers in medicine. 2022 Jan 20; 8:798958. [15] Kato Y, Tsutsui K, Nakano S, Hayashi T, Suda S. Cardioembolic stroke: past advancements, current challenges, and future directions. International Journal of Molecular Sciences. 2024 May 26;25(11):5777. [16] Vicino A, Sirimarco G, Eskandari A, Lambrou D, Maeder P, Dunet V, Michel P. Rare stroke mechanisms in 4154 consecutive patients: causes, predictors, treatment, and outcomes. Neurological Sciences. 2022 Nov;43(11):6359-69. [17] Pang M, Hou S, Xia X, Wang G, Wang Y, Wang L, Li X. Global, regional, and national burden of ischemic stroke attributable to active smoking, 1990–2021. Tobacco Induced Diseases. 2024 Nov 8; 22:10-8332. [18] Fregni F, Almarie B, Martinez R, Olavarría VV, Abanto C, Alet M, Alvarez TF, Amaya P, Ameriso S, Arauz A, Barboza MA. Stroke Burden Attributable to Risk Factors in the Americas, 1990–2021: A Temporal Trends Analysis from the Global Burden of Disease Study 2021. medRxiv. 2025 Jul 11:2025-07. [19] Feigin VL, Owolabi MO, Abd-Allah F, Akinyemi RO, Bhattacharjee NV, Brainin M, Cao J, Caso V, Dalton B, Davis A, Dempsey R. Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission. The Lancet Neurology. 2023 Dec 1;22(12):1160-206. [20] Ding Q, Liu S, Yao Y, Liu H, Cai T, Han L. Global, regional, and national burden of ischemic stroke, 1990–2019. Neurology. 2022 Jan 18;98(3): e279-90. [21] Guo X, Zhang Z, Yin X, QirongXu, Li F, Zhu F. Global burden of ischemic stroke attributable to high body mass index in 204 countries and territories, 1990–2021. BMC Cardiovascular Disorders. 2024 Oct 22;24(1):584. [22] Alsbrook DL, Di Napoli M, Bhatia K, Biller J, Andalib S, Hinduja A, Rodrigues R, Rodriguez M, Sabbagh SY, Selim M, Farahabadi MH. Neuroinflammation in acute ischemic and hemorrhagic stroke. Current neurology and neuroscience reports. 2023 Aug;23(8):407-31. [23] Zhang K, Loong SS, Yuen LZ, Venketasubramanian N, Chin HL, Lai PS, Tan BY. Genetics in ischemic stroke: Current perspectives and future directions. Journal of cardiovascular development and disease. 2023 Dec;10(12):495. [24] Guo YiWang GY, Li PengYue LP, Guo QingLi GQ, Shang KeXin SK, Yan Dan YD, Du ShouYing DS, Lu Yang LY. Pathophysiology and biomarkers in acute ischemic stroke-a review. [25] Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia-the ischemic penumbra. Stroke. 1981 Nov;12(6):723-5. [26] Hofmeijer J, van Putten MJ. Ischemic cerebral damage: an appraisal of synaptic failure. Stroke. 2012 Feb;43(2):607-15. [27] Bandera E, Botteri M, Minelli C, Sutton A, Abrams KR, Latronico N. Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke: a systematic review. Stroke. 2006 May 1;37(5):1334-9. [28] Chan BP, Wong LY, Tan BY, Yeo LL, Venketasubramanian N. Dual antiplatelet therapy for the acute management and long-term secondary prevention of ischemic stroke and transient ischemic attack, an updated review. Journal of cardiovascular development and disease. 2024 Jan 31;11(2):48. [29] Siller?Matula JM, Trenk D, Krähenbühl S, Michelson AD, Delle?Karth G. Clinical implications of drug–drug interactions with P2Y12 receptor inhibitors. Journal of Thrombosis and Haemostasis. 2014 Jan 1;12(1):2-13. [30] Berger J, Ren X, Na B, Whooley MA, Schiller NB. Relation of concentric remodeling to adverse outcomes in patients with stable coronary artery disease (from the heart and Soul Study). The American journal of cardiology. 2011 Jun 1;107(11):1579-84. [31] Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. stroke. 2018 Mar; 49(3): e46-99. [32] De Matteis E, Ornello R, De Santis F, Foschi M, Romoli M, Tassinari T, Saia V, Cenciarelli S, Bedetti C, Padiglioni C, Censori B. Beyond RCTs: short-term dual antiplatelet therapy in secondary prevention of ischemic stroke and transient ischemic attack. European Stroke Journal. 2024 Dec;9(4):989-99. [33] Li M, Huo X, Chang Q, Liu X, Zhang J, Mao Z. Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis. Frontiers in Pharmacology. 2024 Nov 7; 15:1475021. [34] Choi DW. Excitotoxicity: still hammering the ischemic brain in 2020. Frontiers in neuroscience. 2020 Oct 26; 14:579953. [35] Williamson J, Hughes CM, Cobley JN, Davison GW. The mitochondria-targeted antioxidant MitoQ, attenuates exercise-induced mitochondrial DNA damage. Redox biology. 2020 Sep 1; 36:101673. [36] Wang XX, Mao GH, Li QQ, Tang J, Zhang H, Wang KL, Wang L, Ni H, Sheng R, Qin ZH. Neuroprotection of NAD+ and NBP against ischemia/reperfusion brain injury is associated with restoration of sirtuin-regulated metabolic homeostasis. Frontiers in Pharmacology. 2023 Mar 28; 14:1096533. [37] Chen J, Li X, Xu S, Zhang M, Wu Z, Zhang X, Xu Y, Chen Y. Delayed PARP-1 inhibition alleviates post-stroke inflammation in male versus female mice: differences and similarities. Frontiers in Cellular Neuroscience. 2020 Apr 3; 14:77. [38] Bratkowski M, Burdett TC, Danao J, Wang X, Mathur P, Gu W, Beckstead JA, Talreja S, Yang YS, Danko G, Park JH. Uncompetitive, adduct-forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease. Neuron. 2022 Nov 16;110(22):3711-26. [39] Haider K, Haider MR, Neha K, Yar MS. Free radical scavengers: An overview on heterocyclic advances and medicinal prospects. European Journal of Medicinal Chemistry. 2020 Oct 15; 204:112607. [40] Saha S, Buttari B, Panieri E, Profumo E, Saso L. An overview of Nrf2 signaling pathway and its role in inflammation. Molecules. 2020 Nov 23;25(22):5474. [41] Cipriano A, Viviano M, Feoli A, Milite C, Sarno G, Castellano S, Sbardella G. NADPH oxidases: from molecular mechanisms to current inhibitors. Journal of medicinal chemistry. 2023 Aug 31;66(17):11632-55. [42] Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Frontiers in pharmacology. 2018 Nov 6; 9:1157. [43] Noh MY, Kwon HS, Kwon MS, Nahm M, Jin HK, Bae JS, Kim SH. Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions. Molecular Neurodegeneration. 2025 Jul 10;20(1):82. [44] Chen S, Wu L, Lang B, Zhao G, Zhang W. Sphingosine 1-phosphate receptor 1 modulators exert neuroprotective effects in central nervous system disorders. Frontiers in Pharmacology. 2025 May 14; 16:1516991. [45] Moore GW, Castoldi E, Teruya J, Morishita E, Adcock DM. Factor V Leiden-independent activated protein C resistance: communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee. Journal of Thrombosis and Haemostasis. 2023 Jan 1;21(1):164-74. [46] Cui J, Chen S, Zhang C, Meng F, Wu W, Hu R, Hadass O, Lehmidi T, Blair GJ, Lee M, Chang M. Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Molecular neurodegeneration. 2012 May 15;7(1):21. [47] Carman AJ, Mills JH, Krenz A, Kim DG, Bynoe MS. Adenosine receptor signaling modulates permeability of the blood–brain barrier. Journal of Neuroscience. 2011 Sep 14;31(37):13272-80. [48] Cha Z, Qiao Y, Lu Q, Wang Q, Lu X, Zhou H, Li T. Research progress and challenges of stem cell therapy for ischemic stroke. Frontiers in Cell and Developmental Biology. 2024 Jul 8; 12:1410732. [49] Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. science. 1998 Nov 6;282(5391):1145-7. [50] Luo X, Liu Z, Xu R. Adult tissue-specific stem cell interaction: novel technologies and research advances. Frontiers in Cell and Developmental Biology. 2023 Sep 21; 11:1220694. [51] Bieback K, Brinkmann I. Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy. World journal of stem cells. 2010 Aug 26;2(4):81. [52] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. cell. 2006 Aug 25;126(4):663-76. [53] Singh VK, Saini A, Kalsan M, Kumar N, Chandra R. Describing the stem cell potency: the various methods of functional assessment and in silico diagnostics. Frontiers in cell and developmental biology. 2016 Nov 22; 4:134. [54] Craig AJ, Housley GD. Evaluation of gene therapy as an intervention strategy to treat brain injury from stroke. Frontiers in Molecular Neuroscience. 2016 May 24; 9:34. [55] Hofmeijer J, van Putten MJ. Ischemic cerebral damage: an appraisal of synaptic failure. Stroke. 2012 Feb;43(2):607-15. [56] Butt MH, Zaman M, Ahmad A, Khan R, Mallhi TH, Hasan MM, Khan YH, Hafeez S, Massoud EE, Rahman MH, Cavalu S. Appraisal for the potential of viral and nonviral vectors in gene therapy: A review. Genes. 2022 Jul 30;13(8):1370. [57] Nóbrega C, Mendonça L, Matos CA. Gene therapy strategies: gene augmentation. In A handbook of gene and cell therapy 2020 Jun 28 (pp. 117-126). Cham: Springer International Publishing. [58] Markosyan V, Safiullov Z, Izmailov A, Fadeev F, Sokolov M, Kuznetsov M, Trofimov D, Kim E, Kundakchyan G, Gibadullin A, Salafutdinov I. Preventive triple gene therapy reduces the negative consequences of ischemia-induced brain injury after modelling stroke in a rat. International Journal of Molecular Sciences. 2020 Sep 18;21(18):6858.

Copyright

Copyright © 2026 Chetan Sharma , Arun Gorka, Ravi Kumar, Savita , Kapil Kumar Verma. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.